» Articles » PMID: 8317547

Immunohistochemical Study of P53 in Human Lung Carcinomas

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1993 Jul 1
PMID 8317547
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Immunohistochemical analysis of p53 protein was carried out on 95 lung carcinomas from all histological types, including 60 primary tumors, 35 lymph node metastases, and 36 corresponding nude mice xenografts, using four antibodies: PAb240 specific for some mutant conformations; PAb421, PAb1801, and CM1 reactive with most of the forms of p53. Nuclear staining with at least two of those four antibodies revealed the presence of an accumulated protein, considered as indicative of a missense mutation in the p53 gene, in 50% of primary tumors of all histological types, except carcinoids. Some defect of messenger RNA expression was detected by Northern blot analysis in an additional 26% of tumors. p53 immunophenotype of the original tumor was fairly maintained on nude mice. p53 accumulation was not correlated with survival, but with disease extension (P = 0.01). Finally, immunohistochemical analysis allowed the recognition of p53 mutant immunophenotype in 41% of tumors where p53 DNA and messenger RNA were apparently normal, using standard molecular biology. Thus, this method provides a rapid and efficient approach for studying p53 mutations leading to an accumulated protein in lung tumors cells.

Citing Articles

Sodium Valproate Inhibits Small Cell Lung Cancer Tumor Growth on the Chicken Embryo Chorioallantoic Membrane and Reduces the p53 and EZH2 Expression.

Slekiene L, Stakisaitis D, Balnyte I, Valanciute A Dose Response. 2018; 16(2):1559325818772486.

PMID: 29760602 PMC: 5944146. DOI: 10.1177/1559325818772486.


Clinical implication of p53 mutation in lung cancer.

Campling B, El-Deiry W Mol Biotechnol. 2003; 24(2):141-56.

PMID: 12746555 DOI: 10.1385/MB:24:2:141.


Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival.

Gu C, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K Ann Surg. 2001; 235(1):133-9.

PMID: 11753052 PMC: 1422405. DOI: 10.1097/00000658-200201000-00017.


Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.

Dursun B, Memis L, Dursun A, Bayiz H, Ozkul M Pathol Oncol Res. 1999; 5(4):285-90.

PMID: 10607923 DOI: 10.1053/paor.1999.0185.


p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B Br J Cancer. 1999; 80(12):1987-94.

PMID: 10471051 PMC: 2363153. DOI: 10.1038/sj.bjc.6690632.


References
1.
Benchimol S, Pim D, Crawford L . Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J. 1982; 1(9):1055-62. PMC: 553162. DOI: 10.1002/j.1460-2075.1982.tb01296.x. View

2.
McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter K . The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer. 1992; 66(4):735-8. PMC: 1977415. DOI: 10.1038/bjc.1992.348. View

3.
Mercer W, Baserga R . Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Exp Cell Res. 1985; 160(1):31-46. DOI: 10.1016/0014-4827(85)90233-2. View

4.
Isobe M, Emanuel B, Givol D, Oren M, Croce C . Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986; 320(6057):84-5. DOI: 10.1038/320084a0. View

5.
Mountain C . A new international staging system for lung cancer. Chest. 1986; 89(4 Suppl):225S-233S. DOI: 10.1378/chest.89.4_supplement.225s. View